中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
A novel arctigenin-containing latex glove prevents latex allergy by inhibiting type I/IV allergic reactions

文献类型:期刊论文

作者Wang Yong-Xin1; Xue Dan-Ting1; Liu Meng1; Zhou Zheng-Min2; Shang Jing1,3,4
刊名chinese journal of natural medicines
出版日期2016-03-01
卷号14期号:3页码:185-195
关键词Latex allergy Arctigenin RBL-2H3 cell Mouse primary spleen lymphocytes
英文摘要the present study aimed at developing a natural compound with anti-allergic effect and stability under latex glove manufacturing conditions and investigating whether its anti-allergic effect is maintained after its addition into the latex. the effects of nine natural compounds on growth of the rbl-2h3 cells and mouse primary spleen lymphocytes were determined using mtt assay. the compounds included glycyrrhizin, osthole, tetrandrine, tea polyphenol, catechin, arctigenin, oleanolic acid, baicalin and oxymatrine. an elisa assay was used for the in vitro anti-type i/iv allergy screening; in this process beta-hexosaminidase, histamine, and il-4 released from rbl-2h3 cell lines and ifn-gamma and il-2 released from mouse primary spleen lymphocytes were taken as screening indices. the physical stability of eight natural compounds and the dissolubility of arctigenin, selected based on the in vitro pharmacodynamaic screening and the stability evaluation, were detected by hplc. the in vivo pharmacodynamic confirmation of arctigenin and final latex product was evaluated with a passive cutaneous anaphylaxis (pca) model and an allergen-specific skin response model. nine natural compounds showed minor growth inhibition on rbl-2h3 cells and mouse primary spleen lymphocytes. baicalin and arctigenin had the best anti-type i and iv allergic effects among the natural compounds based on the in vitro pharmacodynamic screening. arctigenin and catechin had the best physical stability under different manufacturing conditions. arctigenin was the selected for further evaluation and proven to have anti-type i and iv allergic effects in vivo in a dose-dependent manner. the final product of the arctigenin-containing latex glove had anti-type i and iv allergic effects in vivo which were mainly attributed to arctigenin as proved from the dissolubility results. arctigenin showed anti-type i and iv allergic effects in vitro and in vivo, with a good stability under latex glove manufacturing conditions, and a persistent anti-allergic effect after being added into the latex to prevent latex allergy.
WOS标题词science & technology ; life sciences & biomedicine
类目[WOS]integrative & complementary medicine ; pharmacology & pharmacy
研究领域[WOS]integrative & complementary medicine ; pharmacology & pharmacy
关键词[WOS]natural-rubber latex ; contact-dermatitis ; mast-cells ; degranulation ; calmodulin ; pathway ; asthma ; lignan
收录类别SCI
语种英语
WOS记录号WOS:000373167200003
源URL[http://ir.nwipb.ac.cn/handle/363003/5711]  
专题西北高原生物研究所_中国科学院西北高原生物研究所
作者单位1.China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Jiangsu, Peoples R China
2.Jiangsu Guotai Int Grp Cooperat, Zhangjiagang 215600, Peoples R China
3.Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Key Lab Tibetan Med Pharmacol & Safety Ev, Xining 810008, Peoples R China
4.China Pharmaceut Univ, Jiangsu Key Lab TCM Evaluat & Translat Res, Nanjing 210009, Jiangsu, Peoples R China
推荐引用方式
GB/T 7714
Wang Yong-Xin,Xue Dan-Ting,Liu Meng,et al. A novel arctigenin-containing latex glove prevents latex allergy by inhibiting type I/IV allergic reactions[J]. chinese journal of natural medicines,2016,14(3):185-195.
APA Wang Yong-Xin,Xue Dan-Ting,Liu Meng,Zhou Zheng-Min,&Shang Jing.(2016).A novel arctigenin-containing latex glove prevents latex allergy by inhibiting type I/IV allergic reactions.chinese journal of natural medicines,14(3),185-195.
MLA Wang Yong-Xin,et al."A novel arctigenin-containing latex glove prevents latex allergy by inhibiting type I/IV allergic reactions".chinese journal of natural medicines 14.3(2016):185-195.

入库方式: OAI收割

来源:西北高原生物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。